Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Amy D ShapiroAteefa ChaudhuryMichael WangMiguel A EscobarElisa TsaoChristopher BarnowskiJing FengNisha JainDoris V QuonPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
Recombinant factor IX fusion protein prophylaxis improved bleed control, reduced overall consumption, reduced frequency of infusion and improved compliance for patients with haemophilia B in a real-world setting.